正在加载公司
US$0.73-4.9%11月13日 收盘
数据截至2026年6月30日，来自2026年10月26日提交的6-K
历史表现
- 1W
- -22.5%
- 1M
- -53.1%
- 3M
- -72.7%
- 6M
- -91.5%
- 1Y
- -93.0%
US$0.73-4.9%11月13日 收盘
数据截至2026年6月30日，来自2026年10月26日提交的6-K
取自公司自己的 6-K 文件。
“The first half of 2026 marked a period of profound structural execution and milestone achievement for SL Science. We successfully closed our business combination on June 12, and listed on the Nasdaq Global Market on June 15, supported by a concurrent $7.8 million PIPE financing. This capitalization provides the foundational strength required to advance our clinical programs. Concurrently, our deliberate pivot from direct retail to a B2B wholesale distribution model in Taiwan yielded immediate results. We drove a 23% increase in top-line revenue and expanded our gross margin to over 40% through enhanced volume predictability and optimized supplier pricing agreements,”
逐字引自公告，且只在文件将其归于具名人士时才展示。
SL Science Holding Limited is a biomedical company specializing in developing innovative cellular and gene therapies. Established with a commitment to advancing regenerative medicine and cancer treatment, the Company hopes to utilize immune cell technologies to target cancer, thus potentially offering expansive medical applications for its products. With technologies such as Gamma Delta T cells targeting solid tumor indications including pancreatic and brain cancers, SL Science aims to create cellular therapies that the Company believes have the potential to advance the cell therapy and immuno-oncology sector within the broader biopharmaceutical industry.
公司自己的描述，取自公告末尾。
引述和公司简介来自 SL Science Holding Ltd 于 2026年10月26日 随业绩提交的 6-K 文件；表格根据其季度报告编制。 在 EDGAR 上阅读公告 股价已按拆股和分红复权。
暂无 SL Science Holding Ltd 的业绩电话会文字记录。